BioNTech SE (BNTX)
BioNTech SE Return on Capital Employed (ROCE)
| Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|
| Return on Capital Employed (ROCE) | 0.0% | (22.3%) | (14.7%) | (30.6%) | 6.6% | 149.8% | 55.8% | 2.1% |
BioNTech SE (BNTX) Return on Capital Employed (ROCE) comparison analysis
BNTX key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
investors
worldwide
FAQ
1) What is BioNTech SE's Return on Capital Employed (ROCE)?
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is (5.5%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for BioNTech SE have been 44.2% over the past three years, and 25.7% over the past five years.
2) Is BioNTech SE's Return on Capital Employed (ROCE) Good?
As of today, BioNTech SE's Return on Capital Employed (ROCE) is (5.5%), which is higher than industry median of (50.6%). It indicates that BioNTech SE's Return on Capital Employed (ROCE) is Good.